Faecalibacterium prausnitziiinhibits interleukin-17 to ameliorate colorectal colitis in rats by Zhang, M et al.
Faecalibacterium prausnitzii Inhibits Interleukin-17 to
Ameliorate Colorectal Colitis in Rats
Mingming Zhang1,2, Xinyun Qiu1, Hao Zhang3, Xiaotong Yang1, Na Hong1, Yonghua Yang3*, Hui Chen4,
Chenggong Yu1*
1Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Digestive
Diseases, Huashan Hospital, Fudan University, Shanghai, China, 3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University,
Nanjing, China, 4 School of Medical and Molecular Biosciences, Centre for Health Technology Faculty of Science, University of Technology, Sydney, NSW, Australia
Abstract
Background and Aims: It has been shown that Faecalibacterium prausnitzii (F. prausnitzii), one of the dominant intestinal
bacterial flora, may protect colonic mucosa against the development of inflammation and subsequent inflammatory bowel
disease (IBD), with the underlying mechanisms being unclear.
Methods: The impacts of F. prausnitzii and its metabolites on IL-23/Th17/IL-17 pathway markers were determined in human
monocytes and a rat model of colitis induced by 2,4,6-trinitrobenzene sulfonic acid. F. prausnitzii and its culture medium
(containing complete metabolites) were used to treat the rats in vivo, as well as rat splenocytes and human monocytes in
vitro. Inflammatory cytokines were measured in colon tissue, plasma and cell culture medium.
Results: The culture supernatant of F. prausnitzii increased plasma anti-Th17 cytokines (IL-10 and IL-12)and suppressed IL-17
levels in both plasma and colonic mucosa, with ameliorated colonic colitis lesions. This inhibition of IL-17 release has also
been observed in both rat splenocytes and human venous monocytes in vitro. The culture supernatant of F. prausnitzii also
suppressed Th17 cell differentiation induced by cytokines (TGF-ß and IL-6) and bone marrow-derived dendritic cells
(BMDCs) in vitro. The metabolites of F. prausnitzii in the culture supernatant exert a stronger anti-inflammatory effect than
the bacterium itself. F. prausnitzii protected the colon mucosa against the development of IBD by its metabolites,
suggesting a promising potential for the use of F. prausnitzii and its metabolic products in the treatment of IBD.
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Introduction
Inflammatory bowel diseases (IBD), including ulcerative colitis
(UC) and Crohn’s disease (CD), are characterized by recurrent
inflammation in the gastrointestinal tract. The etiology of IBD
remains uncertain to date. It has been hypothesized that an
undesired intestinal mucosal immune response to luminal contents
(e.g., food and bacteria) contributes to the onset of IBD in
genetically susceptible individuals.
A number of studies have suggested that the IL-23/Th17/IL-17
pathway plays an important role in the pathogenesis of IBD. Upon
co-stimulation by IL-6 and transforming growth factor-beta (TGF-
b), native T cells are differentiated into Th17 cells, which release
the transcription factor retinoid-related orphan nuclear receptor
(RORct) and Th17 specific cytokines, such as IL-17, IL-17F, and
IL-22 [1]. IL-17 released by Th17 cells in turn induces the
expression and release of matrix metalloproteases, chemokines and
proinflammatory cytokines (eg. TNF-a and IL-6) to mediate
monocyte infiltration into the intestinal tissues resulting in tissue
damage [2]. IL-17 is also involved in the regulation of neutrophil
proliferation, maturation, and chemotaxis [2]. Previous studies
have found that IL-17 levels are increased in both serum and
colonic mucosa of patients with IBD, compared to those with
infectious or ischemic colitis. IL-23 is produced by activated
dendritic cells (DCs), which are an essential upstream regulator of
Th17 cells, to keep Th17 cells active and functioning [3]. On the
other hand, members of the IL-12 cytokine family, such as IL-12
and IL-27, have anti-IL-17 characteristics, which can induce the
expression of T box in the T cells (Tbet) and suppress the
differentiation and functions of Th17 cells [4,5].
UC is commonly induced by 2,4,6-trinitrobenzene sulfonic acid
(TNBS) in a rat model, which displays similar pathological changes
in colorectal tissue as those observed in patients with colorectal
colitis. The lesions include mucosal hemorrhages, tissue apoptosis,
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crypt abscesses, neutrophil infiltration, and increased Th17 cell
infiltration in the lesion area [6]. Interestingly, IL-17 receptor
deficient mice were less likely to develop colitis after TNBS
administration [6]. This may be due to high circulating levels of
IFN-c linked to IL-17 receptor deficiency, which can protect mice
from developing an IBD-like phenotype [6]. Furthermore, the
administration of either anti-IL-17 or anti-IL-23 antibodies can
significantly ameliorate intestinal inflammation in animal models
of CD and UC [7,8]. These findings highlight the critical role of
IL-17 in the pathogenesis of IBD-like injury.
Intestinal floral homeostasis has been suggested to contribute to
the protective mechanism of the intestinal mucosa against the
development of chronic inflammation, including those linked to
IBD [9]. The Faecalibacterium prausnitzii (F. prausnitzii) bacte-
rium accounts for 7% of total fecal bacteria and is one of the
predominant bacterial groups in human feces [10]. F. prausnitzii
metabolizes intestinal lactate to produce butyric acid, which is the
main source of generating ATP for the intestinal epithelium
[11,12]. Decreased gut levels of F. prausnitzii can result in an ATP
shortage in the epithelial cells, thereafter weakening the capacity of
self-defense against inflammatory reactions [12]. Butyrate, per se
has been shown to possess anti-inflammatory properties [13],
which may also contribute to the anti-inflammatory effect of F.
prausnitzii [14].
In patients with IBD, the concentrations of both fecal F.
prausnitzii and butyric acid were significantly lower compared to
the healthy controls [15,16]. Although fecal bacteria cannot
accurately represent the segmental distribution of the colonic
mucosa-associated bacteria (MAB), this evidence still suggests that
F. prausnitzii may be vital in the host defense against the
development of IBD [17]. Indeed, in patients with IBD, probiotics
supplementation has been shown to significantly reduce colonial
mucosal inflammation and ameliorate IBD-related symptoms
[14,18,19,20]. The mechanisms may involve the inhibition of
pro-inflammatory cytokines (e.g., IL-12 and TNF-a) and the
stimulation of anti-inflammatory cytokine secretion (e.g., IL-10)
[14,18,19,20], whereas its impact on the IL-23/Th17/IL-17
pathway has not been examined. Nevertheless, the supplementa-
tion of F. prausnitzii may change the enteric microbiotic
homeostasis in patients to improve IBD-related lesions and
symptoms.
The hypothesis of this study is that the culture supernatants of
F. prausnitzii (containing the complete metabolites of F.
prausnitzii) can ameliorate the development of colorectal UC in
rats by inhibiting the differentiation and proliferation of Th17
cells. In this study, the impacts of F. prausnitzii and its culture
supernatants on the development of UC in Sprague Dawley (SD)
rats administered TNBS were determined, along with the effect on
the differentiation and cytokine release of Th17 cells from both rat
splenocytes and human blood monocytes in vitro. The probiotic
Bifidobacterium longum (B. longum) was used as a positive control,
which has been shown to inhibit IL-17 release and colitis
formation in mice [21].
Materials and Methods
2.1. Ethics approval
Both human and animal experiments were approved by the
Ethical Committee of Medical Research, Nanjing Drum Tower
Hospital, Affiliated Hospital of Nanjing University Medical
School. All healthy participants gave informed consent for human
blood cell collection.
2.2. Bacterial culture
F. prausnitzii ATCC27766 (ATCC, Manassas, VA, USA) was
cultured in LYHBHI medium [Brain–heart infusion (37 g/L, BD,
Franklin Lakes, NJ, USA), yeast extract (5 g/L, Oxoid, Cam-
bridge, UK), hemin (5 mg/L, Sigma, St. Louis, MO, USA)],
supplied with cellobiose (1 g/L, Sigma, St. Louis, MO, USA),
maltose (1 g/L, Amresco, Solon, OH, USA), and cysteine (0.5 g/
L, Sigma, St. Louis, MO, USA). Bifidobacterium longum
(Shanghai Sine Pharmaceutical Co., Ltd., Shanghai, China) was
cultured in medium containing trypticase (20 g/L Double Spin
Microbiological Products Factory, Beijing, China), yeast extract
(10 g/L, Oxford, Cambridge, UK), glucose (10 g/L, Sigma, St.
Louis, MO, USA), hydrochloric acid cysteine (0.5 g/L, Sigma, St.
Louis, MO, USA), dipotassium hydrogen phosphate (0.04 g/L),
potassium dihydrogen phosphate (0.04 g/L), calcium chloride
(0.008 g/L), and magnesium sulfate heptahydrate (0.008 g/L).
Bacteria were cultured in an anaerobic incubator (97% CO2 and
3% H2, 37uC). The number of live bacteria (colony-forming units,
CFU) was determined according to the absorbance at 600 nm
(A600). Bacteria were cultured until a stationary phase and then
collected with the supernatant lyophilized. Bacterial cells were
then washed and suspended at 16109 CFU/mL in PBS for in vivo
and in vitro studies. For the in vitro study, the lyophilized
supernatant of F. prausnitzii was prepared as 16, 26, 56, and
106 concentrations prior to use. The sodium butyrate stock
solution was 5.834 mmol/ml. All experiments used lyophilized
supernatant unless stated otherwise.
2.3. Modeling of colorectal colitis in rats and treatment
The rats (SD, 6 weeks, males) were obtained from the Animal
Center, Nanjing Drum Tower Hospital (Nanjing, China) and the
in vivo experiment was performed in the same facility. The rats
were treated daily with different reagents (gavage, catheter
1.2 mm in diameter), including PBS, F. prausnitzii (16109
CFU/rat/day), 16 and 56 concentrated supernatant of F.
prausnitzii, and B. longum (16109 CFU/rat/day, Beijing,
Technology Co., Ltd., Beijing, China) for 7 consecutive days.
On day 6 of the oral treatment, colitis was induced by TNBS as
previously described [22]. Briefly, the TNBS (Sigma, St. Louis,
MO, USA) solution was slowly administered in the colon (80 mg/
kg) via a 4.7 mm-diameter catheter (Jiangyin Guoguang Rubber
Product Co., Ltd., Jiangyin, China). The control was administered
with vehicle. On day 8, the rats were weighed and killed using
ether exposure. Colons were removed, measured, and fixed in 4%
formalin for later histology examination. The colon specimens
were then stained with hematoxylin and eosin, and the lesion was
analyzed using Neurath Scoring criteria as previously described
[23] (briefly, 0 = no inflammation; 1 = very low level of leucocyte
infiltration; 2 = low level of leucocyte infiltration; 3 = high level
of leucocyte infiltration, high vascular density, thickening of the
colon wall and 4= transmural leucocyte infiltrations, loss of goblet
cells, high vascular density, and thickening of the colon wall).
2.4. Peripheral blood mononuclear cell (PBMC) culture
PBMCs were isolated from the venous blood of healthy donors
as previously described [24]. Briefly, after Ficoll-Isopaue density
gradient centrifugation (Ficoll-Paque, MP Biomedicals, Carlsbad,
USA), mononuclear cells were collected and washed in RPMI-
1640 medium (Invitrogen, NY, USA) supplemented with 10%
fetal bovine serum (FBS; Invitrogen, NY, USA), L-glutamine
(2 mmol/L), penicillin (100 U/ml) and streptomycin (100 U/ml).
Subsequently, cells were suspended in complete medium (26106
cells/ml) and seeded in a 24-well plate (26106 cells/well). PBMCs
were then treated with 16, 26, 56, and 106 concentrated
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supernatant of F. prausnitzii. After 24 h, the culture supernatant of
the PBMCs was collected and stored at 280uC for cytokine
analysis.
2.5. Primary splenocyte and bone marrow-derived
dendritic cell (BMDC) culture
Untreated 6-week-old SD rats were sacrificed by cervical
dislocation after ether exposure. Cells in the spleen were harvested
and prepared as a single cell suspension in complete medium in a
24-well plate (16107 cells/well). In the control group, splenocytes
were incubated alone or with recombinant human TGF-ß (2 ng/
ml, Peprotech, Rocky Hill, NJ, USA) and recombinant rat IL-6
(20 ng/ml, Peprotech, Rocky Hill, NJ, USA) at 37uC for 72 h. For
the experimental groups, in addition to TGF-ß and IL-6, cells
were treated with culture supernatant of F. prausnitzii, sodium
butyrate (0.05834 mmol/well), denatured F. prausnitzii and B.
longum bacteria (16 107 CFU/well). Each group treatment was
repeated four times. After 72 h, the supernatant of cultured
splenocytes was collected and stored at 220uC for further analysis
[21].
Immature BMDCs were isolated using a protocol modified from
previous publications [25,26]. Briefly, both ends of the rat (6
weeks) femur and tibia bones were cut, and the bone marrow
flushed out using RPMI-1640 medium (Invitrogen, NY, USA).
The tissue was suspended and passed through a nylon mesh to
remove debris. The red cells were removed with red blood cell lysis
buffer (KeyGEN, Nanjing, China). Bone marrow cells (16106
cells) were then cultured in 1 ml complete medium for 7 d in the
presence of recombinant rat IL-4 (10 ng/ml, Peprotech, Rocky
Hill, NJ, USA) and recombinant rat granulocyte-macrophage
colony-stimulating factor (GM-CSF, 10 ng/ml, Peprotech, Rocky
Hill, NJ, USA). At day 7, immature BMDCs were resuspended in
complete medium for maturation. Mature BMDCs (16106 cells/
well) were incubated with LPS (1 mg/ml, from E. coli, Sigma-
Figure 1. Growth and colonic lesion in rats. Body weight change (A). Colon length (B, C). Colon Neurath score (D). Representative images of rat
colonic mucosa (E–I), control group (E); colitis group (F); supernatant group (G); F. prausnitzii group (H); B. longum group (I). Upper and lower panel
magnifications are640 and6200, respectively. Data are the mean 6 SD. n = 7–8. *P ,0.05; **P ,0.01; ****P ,0.001.
doi:10.1371/journal.pone.0109146.g001
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Aldrich, St. Louis, MO, USA) for 12 h and then treated with
culture supernatant of F. prausnitzii (1 ml), sodium butyrate
solution (0.005834 mmol) and denatured F. prausnitzii or longum
bacteria (16106 CFU/well, BMDCs: bacteria = 1:1) at 37uC for
another 12 h. PBS treated BMDCs were used as a control. Each
group treatment was repeated four times. The supernatant was
collected and stored at 220uC.
In another cohort, the BMDC cells were incubated with LPS for
12 h before splenocytes (16107 cells) were added to each well
(BMDCs: splenocytes = 1:10). Subsequently, the cell mixture was
treated with the culture supernatant of F. prausnitzii (1 ml), sodium
butyrate solution (0.005834 mmol), denatured F. prausnitzii or B.
longum bacteria (16106 CFU/well, 1 ml) and incubated for 72 h.
The cell mixture treated with PBS was used as a negative control.
Each group was repeated four times. The supernatant was
collected at 72 h and stored at 220uC.
2.6. ELISA assay
Cytokines (IL-10, IL-17A, IL-12 p70, and IL-23) were
measured using a commercially available ELISA kit (Bender,
Vienna, Austria; SABC, Wuhan, China) according to the
manufacturers’ instructions.
2.7. Immunohistochemistry
Colon specimens were fixed in 4% formalin and embedded in
paraffin. Sections were boiled in Tris-EDTA buffer (pH 9.0) for
20 min and cooled at room temperature. Sections were then
incubated with rabbit anti-rat IL17 antibodies (Abcam, Cam-
bridge, UK) at 4uC for 24 h and then with the corresponding
secondary antibody (Zsbio, Beijing, China) at 37uC for 30 min.
The sections were then treated with immunoperoxidase using the
DAB kit (ZLI-9033 system, Zsbio, Beijing, China). Sections were
scored in a blind manner using a protocol modified from a
previous publication [27].
2.8. SCFA assay
Fresh rat fecal samples were collected from home cages,
weighed, and stored at 280uC. Fecal samples were mixed with
distilled water and centrifuged. The supernatant was removed,
filtered, and mixed with ether and sulfuric acid. After centrifuga-
tion, the ether layer was collected and measured in an Agilent
6890N Gas Chromatograph Machine for SCFA (acetic acid,
propionic acid, isobutyric acid, butyric acid and, isovaleric acid)
concentrations.
2.9. Statistics
Data were expressed as the mean 6 standard deviation of the
mean (SD). The data were analyzed with a one-way ANOVA
followed by a post hoc Duncan test (SPSS 17.0, SPSS Inc.,
Chicago, USA). P ,0.05 was considered significant.
Results
3.1. Body weight and colon histology
At the end of the experiment, compared with the control group,
the rats in the colitis-TNBS treated group had significantly smaller
weight gain, as well as a shorter colon and higher Neurath scores
(P ,0.05; Figures 1A–F). The culture supernatant of F.
prausnitzii significantly ameliorated the weight loss, reduction in
colon length and high Neurath scores observed in rats in the colitis
Figure 2. Plasma cytokine concentrations in rats. IL-10 (A). IL-12 (B). IL-10/IL-12 ratio (C). IL-23 (D). Data are the mean 6 SD. n = 7–8. *P ,0.05;
***, P ,0.003; ****, P ,0.001.
doi:10.1371/journal.pone.0109146.g002
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group (P ,0.05; supernatant vs. colitis groups; Figures 1A–D, F–
G). However, the treatments with either F. prausnitzii bacteria or
B. longum only significantly reduced the Neurath score and body
weight gain (P ,0.05, compared with the colitis group;
Figures 1A–D), without affecting colon length.
Histological examination showed that the rats in the colitis
group developed extensive ulceration in their colons, which
consisted of coagulative necrosis within the lesion surrounded by
large numbers of neutrophils and some mononuclear cells.
Necrosis lesions penetrated deeply into the muscularis propria.
F.prausnitzii and culture supernatant-treated rats only displayed
mild mucosal and/or submucosal inflammation with a relatively
low level of neutrophil infiltration and mild edema (Figures 1E–I).
3.2. Cytokine and intestinal fatty acid levels in rats
Plasma cytokines, such as IL-12, IL-10,the IL-10/IL-12 ratio,
and IL-23, can be used to assess the systemic level of inflammation
[24]. Compared with the control group, plasma levels of IL-12 and
IL-23 in the colitis group were significantly higher (P ,0.05;
Figures 2Band 2D), and the IL-10 levels and IL-10/IL-12 ratio in
the colitis group were significantly lower (Figures 2A and 2C).
Plasma levels of IL-10 and the IL-10/IL-12 ratio in the
supernatant group were greater compared with those in the colitis
group (P ,0.05; Figures 2A and 2D). Plasma IL-23 levels were
only reduced by the culture supernatant of F. prausnitzii and B.
longum treatments compared with those in the colitis group
(Figure 2D). In rats, IL-17 can be detected in both plasma and
colon tissue. Compared with the control group, IL-17 levels in
both plasma and colon tissue were greater in the colitis group (P,
0.05; Figures 3A, 3B and 3C–G), and were only decreased by the
culture supernatant of F. prausnitzii (P ,0.05; colitis vs.
supernatant groups; Figures 3A, 3B and 3C–G).
In the colitis rats, the net concentrations of butyric acid, total
fecal short chain fatty acid (SCFA) and the percentage of butyric
acid of the total SCFA was significantly lower than that in controls
(P ,0.05; Figure 4D and 4F). Compared with the colitis group,
fecal concentrations of butyric acid and total SCFA, as well as the
percentage of butyric acid in the supernatant group and F.
prausnitzii group, were higher (P ,0.05; Figures 4D and 4F). The
percentages of the other SCFAs of the supernatant group were
significantly lower compared with the colitis group (Figures 4A, 4B
and 4C–E). Of note, the SCFA concentrations in the reconstituted
culture supernatant (16, 56) used for this study are listed in
Table 1.
3.3. Anti-inflammatory cytokine release in human
peripheral blood mononuclear cells (PBMCs) in vitro
PBMCs were sourced from the venous blood of healthy adults.
The effects of culture supernatant of F. prausnitzii on IL-10, IL-12
and the IL10/IL-12 ratio release displayed a dose-dependent
effect, with the greatest impact observed at the lowest concentra-
tion (Figures 5A, 5B and 5C).
Figure 3. IL-17 protein expression in rat plasma and colon. Plasma IL-17 concentrations in the rat (A). IL-17 protein immunohistochemical
staining in rat colon (B). n = 7–8. Data are the mean 6 SD. ****P ,0.001. Representative immunohistochemical staining of IL-17 in rat colon mucosa
in the control (C), colitis (D), supernatant (E), F. prausnitzii (F), and B. longum (G) groups. Upper and lower panel magnifications are640 and6200,
respectively.
doi:10.1371/journal.pone.0109146.g003
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3.4. Th17 cell differentiation in vitro
IL-6 and TGF-b can stimulate native T cells to differentiate into
Th17 cells, which in turn produce and secrete IL-17 [1]. In vitro,
IL-17 release from rat splenocytes was significantly increased by
IL-6 and TGF-b compared with the non-stimulated control group
(P ,0.05; PBS vs. control; Figure 6A). Compared with the PBS
group, IL-17 secretion was significantly lower in cells cultured with
the supernatant of F. prausnitzii (P ,0.05; Fps vs. PBS;
Figure 6A); whereas IL-17 secretions were greater in the
splenocytes co-cultured with F. prausnitzii (Fp) or B. longum
(Bl), compared with the PBS group (P ,0.05; Figure 6A). Butyric
acid, a type of anti-inflammatory substance, was highly present in
Figure 4. Fecal SCFA concentrations and proportion of total SCFA content in rats. (A) Fecal acetic acid concentration and percentage as
total SCFA content. (B) Fecal propionic acid concentration and percentage of total SCFA content. (C) Fecal isobutyric acid concentration and
percentage of total SCFA content. (D) Fecal butyric acid concentration and percentage of total SCFA content. (E) Fecal isovalerate concentration and
percentage of total SCFA content. (F) Fecal total SCFA content. Data are the mean 6 SD. n = 7–8. *, P ,0.05; **, P ,0.01; ***P ,0.003; ****P ,0.001,
compared with the colitis group.
doi:10.1371/journal.pone.0109146.g004
Table 1. Short-chain fatty acids (SCFAs) in fresh cultured and concentrated supernatants.
Culture medium Acetic acid Propionic acid Isobutyric acid Butyric acid Isovalerate
F. prausnitzii fresh (mmol/ml) 3.960.85 0.2260.04 0.1260.01 33.1866.45 0.0760.01
F. prausnitzii 16 (mmol/ml) 3.4660.2 1.1160.06 0.2760.01 5.8360.24 0.5660.02
F. prausnitzii 56 (mmol/ml) 17.2961 5.5760.28 1.3560.07 29.1761.22 2.8160.11
B. longum fresh (mmol/ml) 1.3860.06 2.2160.03 0.0860.01 0.960.03 0.0660
Data are presented as the mean 6 SD. n = 3.
F. prausnitzii fresh, fresh culture supernatant of F. prausnitzii(16108 CFU/ml). F. prausnitzii 16, one time reconstituted culture supernatant of F. prausnitzii. F. prausnitzii
56, five times reconstituted culture supernatant of F. prausnitzii. B. longum fresh, fresh culture supernatant of B. longum(16108 CFU/ml).
doi:10.1371/journal.pone.0109146.t001
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the supernatant of F. prausnitzii (Table 1). To verify its role in
Th17 cell differentiation, we used the same sodium butyrate
concentration as in the supernatant of F. prausnitzii and found
that IL-17 secretion was not significantly changed when spleno-
cytes were cultured with sodium butyrate compared with the PBS
group (P ,0.05; Figure 6A).
Immature bone marrow dendritic cells (BMDCs) can be
activated by lipopolysaccharide (LPS) to secrete IL-23 [28,29],
which plays an important role in maintaining the stability and
function of Th17 cells [3]. In vitro, IL-23 secretion in the
immature BMDCs was significantly increased by LPS compared
with the non-stimulated control group (P ,0.05; PBS vs. control;
Figure 6C). Compared with the PBS group, IL-23 secretion was
significantly lower only in cells cultured with the supernatant of F.
prausnitzii (P ,0.05; Fps vs. PBS; Figure 6C). When splenocytes
and BMDCs were co-cultured, the IL-17 level was significantly
increased by LPS in the PBS group, compared with the non-
stimulated control group (P ,0.05; Figure 6B). In LPS treated
cells, those incubated with the supernatant (Fps) and B. longum
(Bl) released significantly less IL-17 into the culture medium (P ,
0.05; Figure 6B).
Discussion
The major findings in this study are that the metabolites of F.
prausnitzii in the culture supernatant displayed potent effects that
ameliorated colitis lesions in a rat model with similar features to
those in patients with IBD. The proposed mechanisms resulting
from this study are: 1) the inhibition of inflammatory cytokine (IL-
17) release, and 2) the changes of the ratio in inflammatory
cytokines (i.e., IL-10/IL-12) released by monocytes.
Figure 5. IL-10 and IL-12 release from healthy human PBMCs.
IL-10 (A). IL-12 (B). IL-10/IL-12 ratio (C). Data are the mean 6 SD; n =
10–14. *, P ,0.05; **, P ,0.01; ***, P ,0.003; ****, P ,0.001. Medium, F.
prausnitzii cell culture medium. 16supernatant, one time concentrated
supernatant. 26 supernatant, two times concentrated supernatant. 56
supernatant, five times concentrated supernatant. 106supernatant, ten
times concentrated supernatant.
doi:10.1371/journal.pone.0109146.g005
Figure 6. IL-17 and IL-23 release in vitro. IL-17 release from rat
splenocytes in vitro (A). IL-17 release from co-cultured BMDCs and
splenocytes in vitro (B). IL-23 released from the BMDCs with LPS
stimulation (C). Data are the mean 6 SD; n = 4. *, P ,0.05; ****, P ,
0.001. Cont, control group. PBS, PBS group. Fps, supernatant group. Fp,
F. prausnitzii group. Bl, B. longum group. Sbs, sodium butyrate group.
doi:10.1371/journal.pone.0109146.g006
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The causes of IBD are multifactorial. Recently, it has been
recognized that disturbed intestinal bacterial homeostasis may also
contribute to the onset and recurrence of IBD. Firmicutes and
Bacteroidetes are the dominant bacterial strains in human feces
[10]. Several studies confirmed that a reduction of F. prausnitzii, a
well-known butyrate-producing bacterium, in IBD patients
showed an inverse correlation with disease activity [15,16]. F.
prausnitzii’s metabolic products have been shown to possess anti-
inflammatory properties and it has also been suggested that a
sudden decrease in F. prausnitzii in the mucosa may play a role in
the recurrence of IBD [14]. Subsequent studies have suggested
that the protective effect of F. prausnitzii is due to pro-
inflammatory cytokine inhibition and Treg promotion [20,30].
However, this study found that the protective effect of F.
prausnitzii is partly through Th17 cell inhibition. Therefore, F.
prausnitzii could be a potential alternative for the treatment of
IBD.
Figure 7. Proposed working mechanism of the anti-inflammatory effect of F. prausnitziimetabolic products. The F. prausnitzii metabolic
products act via mechanisms on the IL-23/Th17/IL-17 axis. The F. prausnitziimetabolic products inhibit Th17 activity by inhibiting IL-23 secretion from
the DCs and reduce the number of Th17 cells by inducing the anti-inflammatory cytokines. R stimulation; -| inhibition.
doi:10.1371/journal.pone.0109146.g007
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Both IL-10 and IL-12 can suppress Th17 cell differentiation by
activating its inhibitor Th1 cells [4]. The ratio of IL-10/IL-12 can
be used to assess the anti-inflammatory effects of bacteria in vivo
and in vitro [24]. In the current study, the culture supernatant of
F. prausnitzii could increase both systemic and local inflammatory
cytokines in rats, due to increased levels of IL-10, as well as the IL-
10/IL-12 ratio in the plasma and colonic tissues. It seems that the
culture supernatant of F. prausnitzii exerted stronger anti-
inflammatory effects than F. prausnitzii and B.infantis. The
effects of the culture supernatant of F. prausnitzii were consistent
between the in vivo rat and in vitro human PBMC studies [30].
This indicates that the chemicals released by the F. prausnitzii
play a key role in the anti-inflammatory effects of F. prausnitzii,
which did reduce the colorectal inflammatory lesion induced by
TNBS in rats. Interestingly, probiotic B.infantis was shown to be
able to protect individuals against the development of UC in the
clinic, and therefore, in this study, it was used as a positive control
[21]. however,B. infantis treatment did not have an impact on IL-
10 and IL-12, suggesting that the suppressive effects of B.infantis
on the development of colitis occur via different pathways other
than the IL-10/IL-12 ratio.
IL-23 acts as the upstream regulator of Th17 cells, which is
criticalfor maintaining the stability and activation of Th17 cells
[3]. In this study, circulating IL-23 and IL-17 were both
significantly increased by TNBS treatment, suggesting their
involvement in the onset of UC. IL-23 was markedly suppressed
upon treatment of the culture supernatant of F. prausnitzii. This
suggests that it could be chemicals with short half-lives released by
F. prausnitzii that suppressed IL-23 release. In this study, IL-17
levels in the plasma and colonic mucosa, as well as IL-23 levels in
the plasma, were significantly increased in rats with colitis, which is
similar to patients with CD and UC [8,31,32]. Both IL-23 and IL-
17 levels were significantly lower in the culture supernatant treated
rats, in the face of less developed UC. This suggests that the IL-
23/Th17/IL-17 pathway is an effective target for the treatment of
inflammatory colitis. The culture supernatant of F. prausnitzii still
exerted stronger effects than the bacteria F. prausnitzii and
B.infantis in reducing IL-17 levels. In the short term, this may be
due to the bacteria being unable to produce as many metabolites
as those accumulated in the culture supernatant over time and
therefore having less of an effect in suppressing IL-17. The in vitro
experiments in the rat splenocytes and BMDC further confirmed
this finding in the in vivo rat data. When splenocytes differentiated
into Th17 cells in vitro, they showed a similar cytokine release
profile as those observed in the colitis rats. The culture supernatant
of F. prausnitzii could suppress the secretion of IL-17 by the
splenocytes when they were co-cultured with BMDCs.
Butyric acid is one of the metabolites produced by F. prausnitzii
[11], which is an important energy source for the intestinal
epithelial cells [12] and has an inverse correlation with disease
activity [15,17]. Using gas chromatography, we found that F.
prausnitzii produced large amounts of butyric acid in the culture
supernatant, which could contribute to the significant fecal butyric
acid content and its concentration in F. prausnitzii and the culture
supernatant of F. prausnitzii-administered rats, suggesting that the
bacterium itself is essential for maintaining high levels of butyric
acid in the intestinal lumen. The increase in fecal butyric acid
concentration is causally related to ameliorated tissue lesions,
suggesting that butyric acid may be involved in the prevention of
TNBS-induced colitis in the rat. Indeed, butyric acid has been
shown to have an anti-inflammatory effect in vitro [33,34]. This
study also observed that butyric acid suppressed the inflammatory
cytokine release from rat splenocytes in vitro, although no
significantly difference was observed. This result suggests that
other unknown metabolites, rather than butyric acid, played a key
role in reducing the development of IBD.
In summary, this study showed that metabolites of F. prausnitzii
exerted significant anti-inflammatory effects in colorectal colitis in
rats (proposed working model in Figure 7), which ameliorated the
tissue lesions. As similar anti-inflammatory effects have been
observed in human monocytes, using F. prausnitzii metabolic
products is an option for further investigations on potential
treatments for IBD.
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